Treatment method for MMP-implicated pathologies
US7652070B2 · kind B2 · utility
4Cited by
0References
5Claims
0Family size
Inventor
Key dates
| Filing date | Apr 2, 2007 |
| Grant date | Jan 26, 2010 |
| Priority date | — |
| Expiry date | May 6, 2027 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A treatment method for pathologies in which increased levels of MMP production are implicated in pathogenesis. Examples of such pathologies include pterygium, kerataconus, and macular degeneration. Treatment is based on administration of cysteamine in therapeutically effective amounts. Treatment may be in one of several alternative forms, including eye drops and oral applications. Administration in the form of eye drops may be preferred for pathologies affecting the eyes.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.